CD44 is highly expressed within normal, CML and AML CD34+CD38+ and CD34+CD38− BM cells [53•], likely making it unsuitable as a CML LSC biomarker and a cancer-specific therapeutic target, but downstream signalling may be targetable. This evidence concerns the gene CD38 and chronic myelogenous leukemia, BCR-ABL1 positive.